Abstract
We investigated itraconazole, a new triazole antifungal agent that poorly penetrates ocular tissues after oral administration. We injected itraconazole in doses from 10 to 100 micrograms dissolved in 100% dimethyl sulfoxide into the eyes of New Zealand rabbits. Ocular toxicity studies performed five weeks after administration showed no substantial retinal or histopathologic changes in eyes injected with either 100% dimethyl sulfoxide or 10 micrograms of itraconazole. Higher doses caused focal areas of retinal necrosis. Our results indicated that intravitreal doses of 10 micrograms or less of itraconazole may be beneficial in the treatment of fungal endophthalmitis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Aerts F, Van Cutsem J, DeBrabander M. The activity of ketoconazole and itraconazole against Aspergillus fumigatus in mixed cultures with macrophages or leukocytes. Mykosen 1986; 29: 165–76.
Blumenkranz MS, Steren DA. Therapy of endogenous fungal endophthalmitis: Miconazole or amphotericin B for coccidioidal and candidal infection. Arch Ophthalmol 1980; 98: 1216–1220.
Cauwenbergh G, De Donker P, Stoops K, et al. Itraconazole in the treatment of human mycoses: Review of three years of clinical experience. Rev Infect Dis 1987; 9: 5146–5152.
Cobo LM, Savani DV, Perfect JR, Durack DT. Penetration of ocular tissue and fluids and cerebrospinal fluid by azoles in rabbits. Presented at the Ocular Microbiology and Immunology annual meeting, San Francisco, September 28, 1985.
Fine BS, Zimmerman LE. Exogenous intraocular fungus infections. Am J Ophthalmol 1959; 48: 151–65.
Green WR, Bennett JE, Goos RD. Ocular penetration of amphotericin B. Arch Ophthalmol 1965; 73: 769–75.
Hay RJ, Dupont B, Graybill JR. First International Symposium on Itraconazole: A summary. Rev Infect Dis 1987; 9: S1-S3.
Huang K, Peyman GA, McGetrick J. Vitrectomy in experimental endophthalmitis: Part I-Fungal infection. Ophthalmic Surg 1979; 10: 84–6.
Janssen Pharmaceutica Basic Medical Information Manual for Itraconazole, ed 4. Piscataway, NJ, Janssen Pharmaceutical, 1985.
Maurice DM. Injection of drugs into the vitreous body. In Leopold IH, Burns RP (eds): Symposium on Ocular Therapy 1976; Vol 9. New York, Wiley, PP 59–72.
O'Day DM, Head WS, Robinson RD, et al. Intraocular penetration of systemically administered antifungal agents. Current Eye Res 1985; 4: 131–4.
O'Hara MA, Bode DD, Kincaid MC, et al. Retinal toxicity of intravitreal cefoperazone. Ocular Pharmacol 1986; 2: 177–184.
Perfect JR, Savani DV, Durak DT. Comparison of itraconazole and fluconazole in treatment of cryptococal meningitis and candida pyelonephritis in rabbits. Antimicrob Agents Chemother 1986; 29: 579–83.
Peyman GA, Vastine DW, Raichand M. Symposium: Post-operative endophthalmitis. Experimental aspects and their clinical application. Trans Am Acad Ophthalmol Otolaryngol 1978; 85: 374–85.
Polak A, Odds FC, Ludin E, et al. Correlation of susceptibility test results in vitro with response in vivo: Ketaconazole therapy in a systemic candidiasis model. Chemotherapy 1985; 31: 395–404.
Sobel JD, Muller G. Comparison of itraconazole and ketaconazole in the treatment of experimental candidal vaginitis. Antimicrob Agents Chemother 1984; 26: 266–7.
Souri EN, Green WR. Intravitreal amphotericin B toxicity. Am J Ophthalmol 1974; 78: 77–81.
Stiller RL, Bennett JE, Scholer HJ, et al. Correlation of in vitro susceptibility test results with in vivo response: Flucytosine therapy in a systemic candidiasis model. J Infect Dis 1983; 147: 1070–1077.
Tolentino FT, Foster CS, Lahav M, et al. Toxicity of intravitreous miconazole. Arch Ophthalmol 1982; 100: 1504–9.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schulman, J.A., Peyman, G.A., Dietlein, J. et al. Ocular toxicity of experimental intravitreal itraconazole. Int Ophthalmol 15, 21–24 (1991). https://doi.org/10.1007/BF00150975
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00150975